CLINICAL_TRIALS
trial_result
· 2022-12-28
Clinical Trial Update: Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease [Phase 2]
Summary
Phase 2 trial evaluating hydroxyurea to prevent brain injury in sickle cell disease; study completed with results posted in December 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Johns Hopkins University | Conditions: Sickle Cell Disease, Stroke | Phase 2 | Status: COMPLETED | Results posted: 2022-12-28